PMID: 2113565Jul 1, 1990Paper

Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts

The Journal of Experimental Medicine
D B KaufmanD E Sutherland

Abstract

The high rate of persistent hyperglycemia, termed primary nonfunction, after islet allotransplantation in C57BL/6 mice recipients of B10.BR strain islets, as compared with B10.BR recipients of C57BL/6 islets, led to a series of experiments to determine whether islet allograft primary nonfunction was attributable to technical aspects of the transplant procedure or whether it was a consequence of alloimmunity. Primary nonfunction was prevented by systemic pharmacologic immunosuppression of the host with cyclosporine. Selective immunodepletion of host CD4+ and CD8+ T lymphocytes significantly extended the time of classic rejection but did not significantly affect the rate of primary nonfunction. However, modulation of macrophages by administration to the host of silica completely abolished primary nonfunction. These observations, in conjunction with the immunohistological findings of intense macrophage infiltration in islet allografts from recipients exhibiting persistent post-transplant hyperglycemia, support the hypothesis that primary nonfunction results from a cell-mediated host-immune response of rapid onset that is dependent on macrophages or macrophage byproducts as the main effectors.

References

Oct 1, 1977·Annals of Surgery·C F BarkerW K Silvers
Mar 1, 1985·The Journal of Experimental Medicine·J F Warner, G Dennert
Oct 1, 1986·Transplantation·M GotohA P Monaco
Aug 1, 1987·The Journal of Experimental Medicine·T EspevikM A Palladino
Jun 1, 1988·Transplantation·D B KaufmanD E Sutherland
Sep 19, 1968·The New England Journal of Medicine·G M WilliamsF Milgrom
Jan 1, 1972·Scandinavian Journal of Urology and Nephrology·B NerstromF Lund
Nov 21, 1974·The New England Journal of Medicine·E A ClarkM R Mickey
Jun 1, 1983·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·J L Platt, A F Michael
Jun 1, 1984·Transplantation·R W SchwizerR Evans
Mar 18, 1983·Science·C E MorrowF H Bach
Apr 1, 1984·World Journal of Surgery·D Sutherland

❮ Previous
Next ❯

Citations

Sep 1, 1996·Diabetologia·T Mandrup-Poulsen
Mar 30, 2007·Langenbeck's Archives of Surgery·Reinhard G BretzelMathias D Brendel
Oct 1, 1991·Current Opinion in Immunology·I V Hutchinson
Aug 4, 2001·Clinica Chimica Acta; International Journal of Clinical Chemistry·A PileggiL Inverardi
Apr 17, 2003·The Journal of Surgical Research·Marshall S BakerDixon B Kaufman
Feb 1, 1997·Transplantation Proceedings·X LiuU T Hopt
Jun 1, 1997·Transplantation Proceedings·R BottinoL Inverardi
Jun 1, 1997·Transplantation Proceedings·X LiuU T Hopt
Aug 1, 1997·Transplantation Proceedings·J MendolaR Gomis
Apr 9, 1998·Transplantation Proceedings·M J RewinskiG A Perdrizet
Apr 2, 2004·Nature Reviews. Immunology·Camillo Ricordi, Terry B Strom
Nov 1, 1993·The Journal of Experimental Medicine·K AndoF V Chisari
Jul 2, 2004·ILAR Journal·Juan L ContrerasDevin E Eckhoff
Nov 14, 1997·Transplantation·T OzasaP J Morris
Aug 13, 1998·Transplantation·J MellertU T Hopt
Mar 22, 2002·Transplantation·Lijun BaiAnn M Simpson
Sep 16, 2003·Transplantation·Leila MakhloufMohamed H Sayegh
May 25, 2005·Transplantation·Camillo RicordiRodolfo Alejandro
Nov 22, 2012·Transplantation·Han RoJaeseok Yang
Jan 1, 1994·Transplant International : Official Journal of the European Society for Organ Transplantation·R L MarquetJ N IJzermans

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.